Stopping bisphosphonate therapy in people at risk of bone fractures must be carefully considered
The major rationale for starting anti‐resorptive drug treatment in people with osteoporosis is that the risk of further fractures is 2–4 times and that of mortality 2–3 times as great for someone with a fragility fracture as for other people of the same age. This applies to virtually all fractures, and particularly during the 5 years after a fragility fracture.1,2,3
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.